Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937352 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 3 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 896
- Enrollment target
NCT00937352: Clinical Trial Phase 3 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT00937352 is a Phase 3 study that was terminated before completion, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 896 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00937352, a Phase 3 study, was terminated before completion, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 896 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
Interventions
- DRUG Bapineuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 896 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Why NCT00937352 stopped before completion
NCT00937352 is an interventional study that assigns participants to a tested intervention. The registered 896 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% higher).
The record links to 0 conditions, and to 1 intervention - of which Bapineuzumab is the first listed.
NCT00937352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00937352 about?
NCT00937352 is a clinical study titled "A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease". The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
What is the current status of trial NCT00937352?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 896 participants. The study started on 2009-07. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00937352?
The interventions under investigation include: Bapineuzumab (DRUG).
Who is sponsoring clinical trial NCT00937352?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00937352's enrollment target sits among peer trials
896 361st of 2000 higher than 1,640 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia